Lorlatinib is a targeted drug developed and produced by which company

Lorlatinib, brand name Lorbrena (United States, Canada, Japan) and Lorviqua (European Union), is a targeted anti-cancer drug developed and produced by the American pharmaceutical company Pfizer (Pfizer). The drug is mainly used to treat ALK (anaplastic lymphoma kinase)-positive metastatic non-small cell lung cancer (NSCLC) patients, especially for patients who are resistant to previous treatments with ALK inhibitors such as crizotinib, aletinib or ceritinib.

Pfizer discovered lorlatinib through structure-based drug design in 2014 and received accelerated approval from the U.S. FDA in 2018 for the treatment of patients with ALK-positive metastatic non-small cell lung cancer. Subsequently, the European Union and Japan also successively approved the marketing of the drug. The development of lorlatinib reflects Pfizer's continued innovation in the field of anti-tumor drugs and its in-depth exploration of targeted therapies.

As a third-generation ALK inhibitor, lorlatinib has a strong ability to penetrate the blood-brain barrier and can effectively treat patients with ALK-positive non-small cell lung cancer with brain metastasis. Its unique molecular structure and mechanism of action make it excellent in treating drug-resistant tumors. Pfizer has further verified the efficacy and safety of lorlatinib in different patient groups through continued clinical research and data accumulation.

Currently, lorlatinib is on the market in many countries and regions around the world and is widely used in clinical treatment. Pfizer and CStone Pharmaceuticals (CStone Pharmaceuticals) reached a strategic cooperation in 2021 to jointly promote the development and launch of lorlatinib in the Chinese market. This collaboration marks the official introduction of lorlatinib into the Chinese market, providing Chinese patients with a new treatment option.

In short, lorlatinib, as an innovative drug developed by Pfizer, plays an important role in the treatment of ALK positive non-small cell lung cancer. Its development and launch not only reflect Pfizer's technical strength in the anti-tumor field, but also bring new treatment hope to patients around the world.

Reference materials:https://www.drugs.com/